Wednesday, October 25, 2017

Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group

By Susan Decker and Cynthia Koons
‎October‎ ‎25‎, ‎2017‎ ‎8‎:‎01‎ ‎AM‎ ‎EDT

Group says patents have blocked access to life-saving medicine
Pricey hepatitis C treatment has been a top seller for Gilead
Gilead Sciences Inc.’s U.S. patents on the blockbuster $84,000 hepatitis C treatment Sovaldi were challenged by a consumer group that’s battled the drugmaker around the world over the pricing.

The Initiative for Medicines, Access & Knowledge, a nonprofit focused on how patents affect access to medicine, said that it’s filed petitions with the U.S. Patent Trial and Appeal Board seeking to challenge intellectual-property rights that would keep generic versions of Sovaldi from entering the market.

Read the article at Bloomberg

Navigate This Blog
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs" 

No comments:

Post a Comment